Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir for Chronic Hepatitis B (APOSTLE)
NCT03312023Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Feb 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ledipasvir in hepatitis B (HBV) (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Change of Serum Hepatitis B Surface Antigen Level at 12 weeks and Incidence of Adverse Events Leading to Permanent Discontinuation at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03312023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312023.